LA JOLLA, Calif., Jan. 29, 2020 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (NASDAQ: ARTL), a clinical stage biopharmaceutical company developing therapeutics that modulate the endocannabinoid system, today announced that it will be presenting at the LSX World Congress to be held on February 4-5, 2020 at 133 Houndsditch in London, England.
Gregory D. Gorgas, President and Chief Executive Officer of Artelo Biosciences, is scheduled to present on Tuesday, February 4th at 3:15 p.m., GMT, with one-on-one meetings to be held throughout the conference.
For six years, the LSX World Congress has been bringing together the executives that matter to the future of healthcare and life science strategy, investment, partnering and deal making. In 2020, over 1000 executives will come to London for the internationally renowned LSX World Congress. The industry’s C-suite will be joined by the sector’s most active investors, pharmaceutical industry BD&L teams, R&D leaders, and medical experts who are moving the sector forward.
About Artelo Biosciences
Artelo Biosciences, Inc. is a San Diego-based biopharmaceutical company dedicated to the development and commercialization of proprietary therapeutics targeting the endocannabinoid system and related pathways. Artelo is rapidly advancing a portfolio of broadly applicable product candidates designed to address significant unmet needs in multiple diseases and conditions, including anorexia, cancer, pain, and inflammation. Led by proven biopharmaceutical executives collaborating with highly respected researchers and technology experts, the company applies leading edge scientific, regulatory, and commercial discipline to develop high-impact therapies. More information is available at www.artelobio.com and Twitter: @ArteloBio.
Investor Relations Contact:
Crescendo Communications, LLC